Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Vitrolife, Audiocast, Q3'26

By Inderes10/22/2026, 8:00 AM
Vitrolife

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bronwyn Brophy O’Connor
00:01 - 10:19

Good morning, everyone, and welcome to the Vitrolife AB Group Q3 Earnings Call. I would like to start, as I usually do, with the Q3 highlights. And the first highlight I would like to bring to your attention is our growth in technologies. 21% organic growth in the quarter was driven by all regions. And I have to say, the team is doing an excellent job driving both penetration and utilization of EmbryoScope. The second highlight is that our restructuring programme is on plan and on time. In fact, we have an 8% reduction in headcount. So we have been both efficient and effective at taking out costs. And then finally, the third point I'd like to highlight is our strong earnings per share of 2.94 SEK, and this is driven by improved net income and the share repurchase programme. I'd like to take you on now to the next slide and provide you with a market overview broken down by regions. Starting with the EMEA region in Europe, we saw IVF cycle activity picking up in the quarter. In the Middle East, demand remained subdued, but there are signs of improvement. We saw capital sales were strong in the region and orders on longer shelf-life items started to pick up. So we see this as a green shoot. Reimbursement is improving. We see in Sweden the number of funded cycles has increased from 3 to 6. We see improvements in the reimbursement in Denmark and also in Poland. And there have been some positive announcements from NICE in terms of coverage in the UK, or at least the need for improved coverage in the UK. Next, if we look at the APAC region in terms of China, which is the largest IVF market in the region, IVF cycles are down versus last year. However, other major APAC markets are trending positively, including some that had been flat. Flat. Excuse me, for quite some time. Reimbursement is also improving in this region for married couples. I'd like to highlight that. So in most parts of the APAC region, coverage typically only supports married couples. There have been some announcements as recently as September in Taiwan regarding new measures to stimulate IVF activity. And then finally to the Americas. The Americas has the highest cycle growth of the three regions. We can clearly see that the US market is moving towards an insurance-paid system. As more states mandate coverage, employers are providing insurance for IVF for their employees. The final point I'd like to make on Americas is that clinic chains continue to expand their footprint, buying up independent clinics. Okay, I will move us on now and we will take a look at the performance of EMEA, our largest region in terms of revenue, now accounting for 38% of the total. In the EMEA region, we delivered revenue of 333 MSEK, a strong performance with 11% organic growth. Europe is growing strongly, and there are signs that the Middle East expects a return of cycles, with capital sales increasing in the region. So, this is the point I was making on the previous slide. While we don't see a pickup in day-to-day activity. We do see clinics starting to reinvest. Consumables increased 2% in local currencies. With high growth in Europe impacted by lower demand in the Middle East. Technologies were up 22% in local currencies as clinics invest in EmbryoScope to increase workflow efficiency. I have to say that we are delighted with this performance. EMEA has the highest penetration of time-lapse globally. So the team did a really great job and certainly beat our internal expectations. Genetics grew 15%, driven by the regain of genomic kit accounts. The services part also performed well. And then in relation to gross margin, as you can see from the chart, gross margin is down 0.8%. And this is due to product mix. Okay. We will move on now and take a look at the Americas region. So we delivered 292 MSEK, with an organic growth of 5%. And as you can see from the donut chart, Americas now accounts for 34% of our revenue. Yet again, double-digit growth in North America with a good performance across the entire portfolio in South America. The strategic exit from low-profit Genetics accounts reduced sales but improved profitability for the region as a whole. Consumables delivered plus 8% in local currencies, driven by share gains in media. In fact, we grew double-digit in media in both North and South America; Technologies grew plus 48% in local currencies, driven by strong capital sales in North America. We now have some good traction, and clinics are looking for every opportunity to improve efficiency. Genetics -1% with South America offsetting growth in North America. And as I've explained, this is a strategic decision to exit low-profit Genetics accounts in South America. Gross margin increased 1.1 percentage points to 55.1%, and the market contribution rose to 29.3% from 26%. Okay, finally, we move to the APAC region, where we delivered revenue of 260 million SEK and organic growth of 2%. As you can see from the chart, this is our highest revenue quarter in quite a while, a softer quarter for consumables with -5% organic growth. And this is due to weak demand in China and the phasing of distributor and large chain orders in the APAC region. Technologies performed strongly, increasing by 11%, primarily driven by China. So, despite the soft market conditions in China, we do see clinics continuing to invest in EmbryoScope. Genetics grew 8%, driven by genomic kits and a soft comparable quarter last year in this region. And gross margin here also increased 0.7 percentage points to 61.1%, up from 60.4%. Okay. I'll move on to my final slide before I hand over to Pär. So you all know, or at least you should know at this stage, that the Vitrolife group has a mission to be the leading global partner. We don't want to be number two, we don't want to be number three. We want to be the leading global partner in reproductive health, striving for better outcomes for patients. We have five key strategic pillars, which can be grouped into the following three areas: profitable growth, innovation, and operational excellence. So, how are we doing? How are we performing in terms of advancing our strategy and advancing our mission? Well, when it comes to profitable growth, it is very clear from the results this quarter that we are increasing the penetration and utilization of EmbryoScope across all of our regions. Our key focus market. We explicitly stated that we would double down in North America. We have. And this region is delivering double-digit growth in genetics. Our focus on key tests and profitable markets is improving our profitability when it comes to innovation. I really want to thank the team. I want to thank our commercial team, but I also want to give a shout-out to our innovation team. The Freshness Index of the Vitrolife group, which is a measure of the percentage of revenue coming from products launched in the past three years, is at an all-time high. And again, three years ago, we decided we were going to double down on innovation. It is paying off. In fact, 2027 is set to be our best year on record in terms of new product launches. We have significantly reduced the amount of time to achieve regulatory approvals. So as we all know, in medical devices, you can have the best R&D funnel in the world. But if you cannot navigate the regulatory processes and boards across the globe, you won't launch anything. So, we're really happy with the improvements that we've made in terms of our regulatory pathways. And then when it comes to operational excellence, our restructuring programme is on plan and on time. We see the benefits starting to materialize. We are protecting our EBITDA while making investments in digital capabilities. As an example, we launched a new patient portal in the United States, which is doing really well. And then finally, I want to give a shout out, of course, to the Gothenburg folks. We are developing a state-of-the-art manufacturing facility in Högsbo in Gothenburg. It is progressing really well. And I have to say, the operations team there are doing an outstanding job at building this state-of-the-art facility. So in terms of our strategy, we are advancing very well, doing what we said we would do, and striving ever more forward towards that mission of becoming the leading partner in IVF. And with that, I'll hand you over to Pär.

Pär Ihrskog
10:20 - 19:22

Thank you, Bronwyn. So I will cover the financial highlights for Q3. Starting with some more information about the geographical segments. Bronwyn already covered the sales and gross margin, so I will not repeat that. But on the market contribution. Starting with Americas, we ended up with 86 million SEK, which is a margin improvement, reaching 29.3% versus 26%, and in EMEA, 126 million SEK. 38.0% contributing margin compared to 39.9%. And finally, APAC had 111 million SEK, which represents a contributing margin of 42.8% versus 42.1% last year. So moving on to the highlights of the numbers. We had net sales of 884 MSEK, which is a 6% growth in both SEK and organic terms. Gross income reached 523 MSEK, representing a margin of 59.2% compared to 58.9%. And then finally, our EBITDA was 279 million SEK, an improvement from 253 million SEK in Q3 last year. And it represents a margin of 31.6% compared to 30.3%. The margin increase was driven by higher sales but also somewhat improved gross margins. If you look at the quarterly sales and the EBITDA as a percentage of net sales, we have reached 884 million compared to 835, and over the last three quarters, we have seen a gradual increase. And also, if you look at the EBITDA margin, we have a gradual improvement quarter by quarter. As some of you might remember, in Q2 we had some one-off positive items hitting the result. That is why the 34.4% was temporarily a little bit higher than normal. And then moving to the next slide to explain the journey from last year to this year's sales, starting with 835 MSEK last year, we saw an organic growth excluding exited businesses of 6%. And then we had this negative impact from the exited businesses and the divestment that we announced in December last year, which had a negative impact of 2% on the top line. But also in this quarter, we had a positive currency impact of 2%, which in all in all in MSEK gives us a growth of 6%. If you look at the gross margin development over the last five quarters, we ended up at 59.2%, a slight improvement from Q3 last year. In this quarter, we had a positive impact from the US tariff refund of 9 million MSEK. We also had a small positive mix effect from a somewhat smaller share of genetic services. But on the negative side, we had high material costs, which is a combination of US dollar-purchased materials and also general cost inflation on our raw materials. And then in Q3, we always see a seasonal effect from fixed cost absorption related to manufacturing. So this is a comparison of Q3 to Q2. This effect is approximately 0.7 points. And on the operational expenses, we had a small decrease of 3 million SEK. We do see savings from the restructuring programme both in OpEx but also in cost of goods sold. For the OpEx part, the benefits from the savings are offset this quarter by somewhat higher bad debt provisions, but also by inflation-driven salary increases. We also had a positive effect from currency hitting OpEx of 3 million SEK in the quarter. So I would like to give you an update on where we are. Bronwyn already mentioned this, but here are some more details on the restructuring program. It is on plan and on time with most of the planned activities by the end of Q3 this year, as we communicated in December 2025; as you know, the target scope was to exit GDP and NASCO and some low-profit markets. And we also said that this will give us annual savings of 65 million SEK. So where are we now then. We have delivered most of the identified actions, and that has resulted in a gross headcount reduction of 8%. Over the same period, we have invested in headcount in sales, marketing, IT, and other roles, representing an addition of 2.5% headcount. So, all in all, we have a net headcount reduction of 5.5% compared to December last year when we announced the program. The 8% headcount reduction generates savings of 20 million MSEK in the quarter, showing up both in the cost of goods sold and in OpEx. These savings have been offset by higher material costs we are facing, salary increase-driven inflation, the bad debt provision above normal levels, and costs associated with new hires and the restructuring for which we set aside 55 MSEK in Q3. We have used 43 million SEK by the end of Q3. So just a quick update on the cash flow. Then 224 MSEK in operating cash flow compared to 255 MSEK. And the working capital contributed minus 5 MSEK. Q3 last year saw a positive 37 million SEK contribution. So it was a net effect or a swing effect of 42 million SEK decline. And also, we had somewhat higher tax paid in the quarter compared to Q3 last year. So that explains the 60 million negative impact on the cash flow. But we also had a better starting point this quarter with a higher profit. So that had a positive impact of 34 million SEK. So, all in all, this was the best cash flow quarter of the last four quarters. And I would also like to give you an update on the status of the share repurchase program that we announced in July. The board approved to launch a share repurchase program up to 500 million SEK, running until the end of September. We have purchased shares for 246 million SEK, representing 2,006,695 shares. 2,000,695 shares, which we hold, and that is approximately 2% of the outstanding shares by the end of September. So the program continues under the rules and also the limits provided by the AGM. After up to the end, or until the next AGM. So good progress on the program, in line with our expectations. And then a final recap on the financial numbers; sales were 884 MSEK, 6% organic growth compared to Q3 last year, and a slight improvement in gross margin. EBITDA of 279 million SEK versus 253, a slightly improved EBITDA margin. The same goes for the EBITDA margin, 28.9% versus 27.6%. Net income was 124 million compared to 102 million. And the earnings per share that Bronwyn mentioned 0.94 SEK compared to 0.75 SEK. And in the end, operating cash flow was 224 million compared to 255 million. And our leverage net debt to EBITDA ended up at 0.8 compared to 0.7. And with that, we open the floor for Q&A.

Operator
19:23 - 19:48

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key on your telephone keypad. Please start by asking one question followed by a follow-up question. It is then fine to queue up again for more questions. The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.

Philip Wiberg
19:49 - 20:10

Hi. Good morning. I've got a couple of questions, I believe. So, just in general, quite strong growth now in this quarter. And I was just wondering how much of a temporary effect this is with large orders coming in in Q3. And what do you see as the pipeline now for Q4 and beyond?

Bronwyn Brophy O’Connor
20:12 - 22:51

Yes. So, good morning, Philip. Thank you for your question. We have really been focusing heavily on technologies and on funnel management using Salesforce. We see it as a great opportunity. So it is a fantastic quarter. As I mentioned, we did beat our expectations, but it is a strategic double down. We see it as a great opportunity for the Vitrolife group. If you combine the EmbryoScope with our Eyewitness solution, we are the only player that can offer something of this level of technological advancement. So the goal is certainly to continue to drive forward very strongly in technologies. Now, I consider 21% growth very high. Can we maintain those levels? That is challenging. But we have a fantastic commercial team who are definitely going to try. I think the future looks very good. We did have a very big technologies quarter in Q4 last year. So it is a mountain to climb in terms of the comps, but our funnel looks good. Maybe one other highlight to point out is that in this quarter, we also manufactured and shipped our highest number of EmbryoScope ever. The other positive development we are seeing is that we are able to scale the manufacturing of the EmbryoScope to meet the demand. So, maintaining these types of growth levels, I think will be tough, but we do see a strong and a good pipeline. And look, ultimately, EmbryoScope really helps the workflow efficiency in the lab. Not all time-lapse systems are created equal. They are not. And I say that with all humility. And I think what clinic chains are really starting to realize is that EmbryoScope does provide workflow advantages and efficiencies that other time-lapse systems don't. So, we feel pretty good about technologies. This level of growth, I think, would be tough, but the commercial team is doing a fantastic job at converting leads into sales. You know, the thing is, Philip, if you ask every director of every IVF clinic chain in the world, would you buy an EmbryoScope if you had the money? I can guarantee you most of them would say yes, but of course, it is the affordability piece. And of course, we don't just want to sell capital, we want to drive the utilization as well. So along with the data, hopefully that gives some color and context to your question.

Philip Wiberg
22:53 - 23:22

Yes. Thanks. It definitely does. And just the second one that I have was around China, but I suppose we might have answered it a bit already. You are still talking about China in terms of cyclical growth being down year-on-year now. But still, technology did quite well there. So I was wondering what is driving EmbryoScope adoption there in the soft market. Is that at all any sign that the market is improving, or is it just that they are trying to improve their efficiency?

Bronwyn Brophy O’Connor
23:23 - 24:42

I would see it as more the latter. Philip. I think cycles remain soft. I've spent some time in China, visited a lot of customers, and the feedback was very consistent in terms of cycle growth. But there is, of course, as there is in all clinics around the world, a drive for improved efficiency. China is an area where we doubled down again. We placed capital sales specialists in the region to do exactly what we are doing today to drive penetration and adoption of EmbryoScope. So, tactically, this is what we decided to do in China, knowing that the market was soft again here. The Chinese clinics really like working with EmbryoScope. Also, the combination of EmbryoScope with our media. So we have a very strong media position in China, even with the softer conditions. The clinics in China really like the combination of EmbryoScope and the Vitrolife group media. So I think our strong, dominant media position also helps time-lapse. So in certain parts of the world, we use time lapse to pull through consumables revenue. I think what happens in China is our strong media position helps drive EmbryoScope adoption. So yes.

Philip Wiberg
24:44 - 24:46

Okay. Thank you. I will get back into the queue.

Bronwyn Brophy O’Connor
24:46 - 24:47

Thank you very much, Philip.

Operator
24:50 - 24:54

The next question comes from Jakob Lemke from CIB. Please go ahead.

Jakob Lemke
24:56 - 25:17

Yes. Hi. Good morning. My question is on genetics. When you look at it, if you disregard Latin America, it seems like you are growing volumes across most regions here. So if you could elaborate on what is really behind this and if this is durable going forward.

Bronwyn Brophy O’Connor
25:19 - 27:18

Yeah. So good morning Jakob. Thank you for your question. Yeah. Maybe I will break it down by region. North America is doing very well. It has been for quite a while and it continues to do well. South America is definitely a drag, a significant drag on the total performance of that region. But again, strategically, we decided to exit those low-profit accounts and it is improving our profitability. We believe it's the right thing to do. If you look at the EMEA region, most of our markets are doing very well, some growing slightly above market, but their performance across the board is pretty good in EMEA and APAC. I don't like to pat ourselves on the back because the base is pretty small. Right? But APAC is doing well in genetics. It is doing well. I mean, obviously we don't break down by markets, but I'm looking at the breakdown here and it is doing well in most markets, almost all actually, in fact, in APAC and kits is performing well. Kits has been very challenging for many quarters for me as the CEO, but we take the good times when they come and it's performing well at the moment. We need to continue that momentum. But of course, by far the biggest part of the genetics revenue is genetic services. It is a good quarter, right? It is 5% growth across the board. You know, it is pretty consistent and good performance across most of the markets. Good performance on kits. Now the challenge is for us to keep that momentum going. That is what it is all about and accelerating certain areas where we can. So, we don't break down by markets yet, but hopefully that has answered your question and given you some more context.

Jakob Lemke
27:19 - 27:35

Yeah, that's very helpful. And just on Latin America, when will the impact or sort of headwind from you exiting this low profitability market be completed and the Americas region returning to growth.

Bronwyn Brophy O’Connor
27:36 - 28:05

Yeah. So maybe I'll take the first part. You might help me with the second part. So already we see the declines slowing, although it is a bit early to call whether it, you know. I suppose in terms of exact quarters, it would probably be the end of Q1. Before we start, would you say Pär? And I would say end of Q1. Don't hold me to that. But that would be my best estimate.

Pär Ihrskog
28:05 - 28:07

We see that. We see the trend flattening out.

Bronwyn Brophy O’Connor
28:07 - 28:08

Yes, it is flattening out.

Pär Ihrskog
28:08 - 28:11

Yeah. I think you are right on the Q1 estimate.

Bronwyn Brophy O’Connor
28:11 - 28:24

Yeah. So I would say, Jakob, probably end of Q1. But it is definitely slowing versus the previous quarter for sure.

Jakob Lemke
28:27 - 28:29

Good. I'll get back into the queue.

Bronwyn Brophy O’Connor
28:29 - 28:31

Okay. Thank you very much, Jakob.

Operator
28:34 - 28:38

The next question comes from Ludwig Gemunder from Handelsbanken. Please go ahead.

Ludwig Gemunder
28:40 - 29:05

Yes. Good morning. Thank you for taking my questions. So I have one question and then a follow-up. First, I just want to zoom in on China and hear your thoughts. I just jumped off another call, and they mentioned that they were seeing a slowing economy and slowing consumer spending in China. Is that part of what you are seeing as the reasons behind the slowing cycle growth, or is it just demographics? If you could expand a bit on that, it would be great.

Bronwyn Brophy O’Connor
29:06 - 30:31

Yeah. So Ludwig, it is demographics. So China has almost a perfect storm in terms of demographics. So you have 150 million one-child families in China. So people are accustomed to having one child as a result of the one-child policy, which was in place for close to 40 years. The ratio of males to females is skewed, so there are more men. Males were favored over females. So you have more males of, let's say, reproductive age than you have females. So even if those males want to get married and have children, they cannot find a partner. So it is very much demographic. It is going to be a significant challenge for the Chinese government to turn that around. So that is why they have been increasing reimbursement, paying people to have children, and encouraging people to get married. They need the people of reproductive age to be having more than one child. So it is demographic. Of course, there is an affordability component because IVF is not free in China. But the state aid is improving all the time. So, yeah, I would say it's definitely influenced by economics, but demographics is the biggest lever here.

Jakob Lemke
30:34 - 30:35

Okay.

Ludwig Gemunder
30:35 - 31:01

Thank you. That makes sense. Just a quick follow-up. First, it would be interesting to see if you see any end to this. And then I was also wondering, you mentioned the reimbursements. You also talked about that in the beginning of your presentation, looking at history, how has increased performance affected your sales and the demand you're seeing? And if you could add some timing regarding when improved reimbursements are expected to have an impact, that would be helpful as well.

Bronwyn Brophy O’Connor
31:02 - 34:17

Yeah. So, let me answer the second part of your question first. It takes time. So when reimbursement improves, there is definitely a time lag. So let's take our own backyard here. If we take Sweden. So we see reimbursement has improved. It has improved quite significantly, statistically speaking. And we do see the Nordic region doing well. It is doing pretty well this quarter, but for the reimbursement to feed through the system, it takes time. Because, you know, capacity in clinics is not unlimited. So there are two big factors to consider here. One is access. The other is affordability. If we improve the affordability piece, we also as a society have to work on the access part. So there is definitely a time lag. I think another example of that is the state of California, actually. So if you look at the state of California, it became a mandated state. Employers need to provide IVF coverage for their employees. But it's taken a bit of time to see an uptick in the cycles in California. So it does take time. And then I think the first part of your question, if I understood it correctly, and if I did not, please interject and correct me, do I see an end in sight for China, as in a pickup in cycles for China? Well. Things are going to be quite difficult for China if they do not start producing more babies. By the way, this is the same globally. If the world does not start having more children, who is going to pay the pensions of the aging societies? We have inverted population pyramids in most major countries around the world. If you look at the G20, less than a handful of the G20 countries have a birth rate at 2.1 or above, which is what you need to sustain your population. It is not good news for China, but it is clear that the government is taking stronger measures to try to stimulate the birth rate. And this is a global phenomenon and the Americans are doing it. The Swedes are doing it. It's happening all over the world. The Koreans are doing it. The Taiwanese are doing it. The Japanese are doing it. Economics do not look good for any of us if people do not start having children. Is it likely to pick up very quickly? I personally do not think so. But it has to pick up, or economically we're not going to be in a good place. So I don't know if you read The Economist, but if you read The Economist every week, which I do, I am an economist junkie. It is extremely rare that there isn't an article in The Economist on the problems that we are going to have as a society if we don't start having more babies. All right. Thank you for your questions. Yeah.

Ludwig Gemunder
34:18 - 34:18

Thank you.

Operator
34:22 - 34:27

The next question comes from Albin Ryott from ABG Sundal Collier. Please go ahead.

Albin Ryott
34:28 - 35:05

Uh, yes. Good morning, Bronwyn and Pär. I hope you are well and hope you can hear me. Perhaps beginning a little bit with the commentary surrounding the order phasing to larger chains and distributors, which you state are or seem to be mainly tied to APAC. But EMEA consumables growth really was only 2%, I believe, in the quarter. Does this lower growth rate primarily reflect the negative effect you are seeing from the Middle East? What is the underlying growth rate you are seeing in the Western Europe markets for consumables, for your part and for cycles?

Bronwyn Brophy O’Connor
35:06 - 37:21

Yeah. So, most of the distributor and the clinic chain phasing is coming from APAC. So just to be clear on that one. So Western Europe is doing well. We have good growth across all of our major markets in Western Europe, which is really nice to see. Europe had been a little bit sluggish. So it is good to see some rebound. Regarding the Middle East. So what we see in the Middle East is good growth on the technology side. We have good growth across all of our major markets in Western Europe, which is really nice to see. Europe had been a little bit sluggish. So it's good to see some rebound. The Middle East. So what we see in the Middle East is good growth on the technology side. So we do see investment in capital equipment. But the consumables piece, or more specifically media, is still down. So media has a short shelf life. So clinics are not stocking up on media in anticipation of IVF cycles coming. No clinic is going to do that. But we do see green shoots in terms of other parts of the portfolio in the Middle East. As I said, there is good investment in time-lapse, which is nice to see. And then regarding some of the longer shelf life items. There is also a pickup there. I guess the thing you have to remember with IVF is that, sadly for patients, it remains the same whether there is a war or if we want to use the polite term, a geopolitical situation. So irrespective of the geopolitical situation, a patient's window for IVF is very small. And this geopolitical situation has been going on since the first quarter of the year. So the clock starts to tick for patients. You can only delay your IVF treatment for so long; your window really starts to close. Patients start to become anxious and need to get going. So I think that is what we are starting to see now in the Middle East, despite the fact that the situation is still very difficult there. You know, the IVF window is short, it starts to close, and patients need to get going with their cycles. That is the reality on the ground. Does that help to answer your question, Alvin?

Albin Ryott
37:22 - 37:56

Yes, but maybe if you look at Western Europe consumables growth, is it reasonable to assume then that it is closer to a double-digit organic figure, considering that the Middle East skews the picture? And then another one before I get back in the queue is, is the adjusted growth within Genetics? I believe it ties to Jacob's question earlier and was really strong. I believe it was 15% in Q2. Can you give us some more commentary on what is driving that higher growth rate in EMEA for genetics?

Bronwyn Brophy O’Connor
37:57 - 39:14

Yeah. So I will start with your consumables question. I am not going to break it down by percentages. We do not divulge that. But I would say high single digits in consumables across Western Europe. So that's good. But it is pulled down, as I said, by the Middle East and media being the culprit there. And then your question on genetics. Yes, we do have good growth in genetics also in Europe, with a couple of markets in particular doing strongly. But we have also regained some kit business that we lost. So we lost some genomic kit business. I believe it was around midway through last year. We have regained that kit business. So that is also driving the total genetics performance in the region. So you have good performance on the services side, nice performance in Western Europe. And then you have the extra driver of the regained genomic kit business.

Albin Ryott
39:18 - 39:22

Thank you so much. I think that answers everything. Thank you so much. I'll get back in line.

Bronwyn Brophy O’Connor
39:23 - 39:24

Okay. Thank you. Alvin.

Operator
39:24 - 39:35

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Jakob Lemke from SEB. Please go ahead.

Jakob Lemke
39:38 - 40:14

Hi. I have a few more questions. I will run through them. First, on the outlook you provided for APAC, it seems like you are a bit more upbeat on most other markets than China. So what are your thoughts on 2027 and a sort of blended cycle growth across your exposure? Do you see that we can grow or that your market volumes will grow in China and that the positivity across the other regions will offset potential declines in China.

Bronwyn Brophy O’Connor
40:16 - 41:29

Yeah. So, I mean, China is the largest IVF market in APAC and the cycles are down, and it's likely to stay that way in 2027. But most of the other markets in APAC are growing. And that includes markets that we haven't seen grow for many years. I am not going to point out competitors who I am sure are eagerly tuned in to where the pots of gold are, but we do see established APAC markets starting to return to growth. It is not very impressive growth. It is lower growth than we see in the Americas or lower growth than we see in Western Europe. But they are growing, and parts of Southeast Asia are growing nicely. So, one would feel better about APAC in 2027. Based on the current trends. Yeah. Does that answer your question? Jakob? I do not want to be too specific on which markets.

Jakob Lemke
41:31 - 41:57

Yes, no, it was very clear. I also have a question around the product launches. I know you've launched a few products this year, and you also commented that for 2027, the question is whether these launches this year have had any meaningful impact on sales growth. And how should we think about the launches you are doing moving forward? When will they have an impact?

Bronwyn Brophy O’Connor
41:58 - 44:40

Yeah. So, back to my point around the freshness index. So our launches are having a positive impact. So the percentage of revenue that we have coming from products launched in the past three years is high. I know exactly what the percentages are. I have spent 30 years working in medtech, and I can tell you it is the highest percentage for freshness index I have seen. So we are doing really well at driving growth of new products. That is a fact. Fact is, as you would say in Swedish, 2027 is going to be a big year. So when I say a big year, I do not just mean in terms of the number of launches; I mean in terms of the specific products, tests, services, and technologies that we are going to launch. It's going to be a really exciting year. So we doubled down on R&D. Three years ago, we rationalized the number of R&D programs. We decided to focus on some big bets. And 2027 is the year when those big bets come out of the gates. Now it takes time for that revenue to filter through. Okay. So don't expect the launch to happen in Q1, or for the revenue to start blowing up, as that is not going to happen. It takes a little bit of time. And of course, these launches roll out regionally. So it depends on where we launch first, but it is very difficult to do a global launch. So you tend to pick your geographies where you want to launch, but 2027 is set to be our best ever year in terms of the number and the size of the launches that we get through the gates. So the team are very excited about that, and I would like to thank all of the innovation team, but specifically Richard Ericsson, who is our senior vice president of innovation. He has been leading the R&D teams, the market access team, and product lifecycle management. They have done a terrific job. The other point and very important point, as I mentioned in my voiceover, is on the regulatory approvals. So we have actually halved the time from previous quarters. We have halved the amount of time that it takes from when we get to toll gate four to launch. So our regulatory paths have shortened significantly. We have a fantastic leader of our market access group who joined Vitrolife AB a couple of years ago. And she has done great work there. So innovation is in a really good place. Jakob.

Jakob Lemke
44:43 - 44:55

Sounds promising. And if I may ask, are these mainly upgrades of existing products or existing product lines, or are they also some sort of completely new products?

Bronwyn Brophy O’Connor
44:56 - 45:31

Oh, I don't want to provide a spoiler now, Jakob; if I tell you, I might have to kidnap you afterwards. They are exciting launches. They are launches that the market is really yearning for. Some are iterative, and some are a little bit more transformative. How about that for some R&D language, iterative and transformative. You're getting very good at extracting information from me, Jakob.

Jakob Lemke
45:34 - 45:46

Okay. Then also just on how you are planning to increase sales headcount going forward, if it is going to continue to be at a high pace or if you are going to slow down a bit.

Bronwyn Brophy O’Connor
45:47 - 45:59

Okay. And I think this will be our last question, right? So, Jakob, you asked me about sales headcount. Yeah, I would say, do you want to take this one?

Pär Ihrskog
46:00 - 46:30

Yes, we have done a small shift. As I explained when I talked about the restructuring programme, we have reduced headcount quite a lot, based on the non-core GPDx assets. Some of the exit of the small markets. At the same time, we have invested in sales and marketing, but also in IT and other functions. So we have done the shift. There is maybe a little bit more to do, but no major changes in headcount additions, but still some more to do. I would say.

Bronwyn Brophy O’Connor
46:31 - 47:30

Yeah. I think what we've done really well is we've managed, particularly this year, to really make sure that we have people on the ground in the markets where we can drive profitable growth. Okay. So we had people on the ground in markets where we could drive growth, but was it the type of growth that we wanted? No, I think what we have now is that our feet on the street are in the markets where we have the greatest opportunity to drive organic growth, but it is growth with higher profits. I am sure our Chief Commercial Officer is listening in. They always want more headcount. Okay. That is the nature of commercial people. They want more. But if they want more, we need to drive faster growth in order to pay for it. Right. So, I would say that we are in pretty good shape on the sales and marketing side. I don't see a big need for further investment there. Yeah.

Jakob Lemke
47:33 - 47:40

Good. Can I just ask very quickly if you can say anything on the new CEO and if there is any update there?

Pär Ihrskog
47:41 - 48:15

Yes, I can cover that. The process is ongoing. First of all, I just want to say that I spent a lot of time with Bronwyn every day, and she is fully dedicated to running this company. She is doing a great job. The board is working very actively to find a new CEO. To my knowledge, the plan is progressing well. And when they have a candidate, they will present it as soon as they have it, but there is good progress on that recruitment.

Jakob Lemke
48:17 - 48:18

Okay. Thanks.

Pär Ihrskog
48:20 - 48:22

Okay. I think that was the last question.

Bronwyn Brophy O’Connor
48:24 - 48:24

Yes.

Operator
48:24 - 48:31

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Bronwyn Brophy O’Connor
48:33 - 49:04

So on behalf of myself and Pär, we would like to thank you most sincerely for dialing into today's call. Thank you for your great questions. You certainly kept me on my toes. I would also like to thank Cecilia Mellstrand, who did an outstanding job preparing both Pär and me for our first earnings call with us. So, I wish you all a wonderful day and thank you very much. Goodbye.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…